Science fiction has become reality: Best practice for future viral pandemics
Published in British Journal of Clinical Pharmacology
Challenge in treating COVID‐19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels
Published in British Journal of Clinical Pharmacology
SARS‐CoV‐2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?
Published in British Journal of Clinical Pharmacology
Will AstraZeneca be able to provide clinical trial data on its COVID‐19 vaccine efficacy in older adults?
Published in British Journal of Clinical Pharmacology
Postvaccination anaphylaxis and mRNA‐based SARS‐CoV‐2 vaccines—Much ado about nothing?
Published in British Journal of Clinical Pharmacology
COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions.
Published in British journal of clinical pharmacology
Extensive hard palate hyperpigmentation associated with chloroquine use.
Published in British journal of clinical pharmacology
A 66-year-old woman diagnosed clinical manifestation of extensive hard palate hyperpigmentation is presented. Due to historic of rheumatoid arthritis and use of chloroquine phosphate for 3 years, exogenous hyperpigmentation associated with the drug was included among the possible diagnoses. Incisional biopsy was performed and the histopathological ...
COVID-19 vaccines: the importance of transparency and fact-based education.
...Published in British journal of clinical pharmacology
Demographics in the 2020s—Longevity as a challenge for pharmaceutical drug development, prescribing, dispensing, patient...
Published in British Journal of Clinical Pharmacology
Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.
Published in British journal of clinical pharmacology
